Pharming (PHAR) EBT Margin (2020 - 2026)
Pharming's (PHAR) quarterly EBT Margin came in at 16.08% in Q2 2026, up 1387.0% YoY from 1.08% in Q2 2025, and up 100.0% on a QoQ basis from 20316921335597.06% in Q1 2026.
Powered by 
Analysis
Pharming (PHAR) EBT Margin (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of EBT Margin data on file, last reported at 16.08% in Q2 2026.
- Quarterly EBT Margin rose 1387.0% year-over-year to 16.08% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 10.24% (up 3946.0% YoY) and the FY2025 annual result came in at 3.42%, up 627.0% from the prior year.
- EBT Margin grew to 16.08% in Q2 2026, from 20316921335597.06% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 2024064.17% in Q3 2024 to a low of 20316921335597.06% in Q1 2026.
- A 5-year average of 1128718792064.15% and a median of 1.1% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin jumped 1064053621 bps — and 2026, when it sank 2000000000 bps.
- Tracing PHAR's EBT Margin over 5 years: stood at 21.92% in 2022, then tumbled by 67485255 bps to 14793103.45% in 2023, then surged by 72 bps to 4152567.24% in 2024, then jumped by 100 bps to 0.0% in 2025, then soared by 356669487 bps to 16.08% in 2026.
- The last three EBT Margin figures came in at 16.08% (Q2 2026), 20316921335597.06% (Q1 2026), and 0.0% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 12.09% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -2.67% |
| 10 | Pharming | 781.07 Mn | 621.57 Mn | 141.47 Mn | -1.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.05% |
| Mar 31, 2026 | -6.02% |
| Dec 31, 2025 | 4.51% |
| Sep 30, 2025 | 13.05% |
| Mar 31, 2025 | -14.53% |
| Dec 31, 2024 | -7.43% |
| Sep 30, 2024 | 2.02% |
| Jun 30, 2024 | -22,515,519.57% |
| Mar 31, 2024 | -28.92% |
| Dec 31, 2023 | -14.79% |
| Sep 30, 2023 | 4.96% |
| Jun 30, 2023 | -24.20% |
| Mar 31, 2023 | -38.40% |
| Dec 31, 2022 | 21.92% |
| Sep 30, 2022 | 17.16% |
| Jun 30, 2022 | 35.53% |
| Mar 31, 2022 | 9.87% |
| Dec 31, 2021 | 13.73% |
| Sep 30, 2021 | -37.16% |
| Jun 30, 2021 | 21.86% |